Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | TPO | P07202 | 1/20 | 0.40 |
| ▸ | EPX | P11678 | 1/20 | 0.40 |
| ▸ | LPO | P22079 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29637517 | 1.00 | DYRK1A (0.53) | DYRK1AGAANPC1SUV39H2NOS3 | |
| SCHEMBL22491094 | 0.83 | GAA (0.50) | DYRK1AGAANPC1SUV39H2NOS3 | |
| SCHEMBL29637494 | 0.80 | NOS3 (0.44) | DYRK1AGAANOS3NOS1NOS2 | |
| SCHEMBL29637497 | 0.80 | NOS3 (0.44) | DYRK1AGAANOS3NOS1NOS2 | |
| SCHEMBL2894993 | 0.80 | NOS3 (0.44) | DYRK1AGAANOS3NOS1NOS2 | |
| SCHEMBL15527815 | 0.80 | AOC3 (0.43) | GAANOS3NOS1NOS2MPO | |
| SCHEMBL558770 | 0.80 | GAA (0.47) | DYRK1AGAANPC1SUV39H2HSP90AA1 | |
| SCHEMBL30503613 | 0.78 | NPC1 (0.43) | DYRK1AGAANPC1HSP90AA1HSP90AB1 | |
| SCHEMBL1424930 | 0.78 | NPC1 (0.43) | DYRK1AGAANPC1HSP90AA1HSP90AB1 | |
| SCHEMBL25347088 | 0.77 | GAA (0.42) | DYRK1AGAANPC1TAAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090317-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260000692-A1 | Substituted N-(Pyridin-2-yl)Acetamide Derivatives as CDK12/13 Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2026-01-01 | — | — | US | disclosed |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| CN-114423758-B | Antibacterial compounds | 爱尔兰詹森科学公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119562812-A | Substituted N- (pyridin-2-yl) acetamide derivatives as CDK12/13 inhibitors | 奥里吉恩肿瘤学有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20240199611-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2024-06-20 | — | — | US | disclosed |
| EP-4028399-B1 | ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2024-02-14 | — | — | EP | disclosed |
| EP-4308239-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396475-A | Antibacterial compounds | 爱尔兰詹森科学公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2024009232-A1 | SUBSTITUTED N-(PYRIDIN-2-YL)ACETAMIDE DERIVATIVES AS CDK12/13 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-01-11 | — | — | WO | disclosed |
| EP-3458066-A1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | Merck Sharp & Dohme Corp. (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017200825-A1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017197555-A1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| CN-100358893-C | Certain novel imidazopyridines and uses thereof | ASTRAZENECA AB (SE) | 2008-01-02 | — | — | CN | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
| CN-1684964-A | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2005-10-19 | — | — | CN | disclosed |
| EP-1539759-A1 | USE OF AND SOME NOVEL IMIDAZOPYRIDINES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004016611-A1 | USE OF AND SOME NOVEL IMIDAZOPYRIDINES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | DYRK1A 792/4885GAA 1462/4885NPC1 2655/4885 |
| US-20260000692-A1 | Substituted N-(Pyridin-2-yl)Acetamide Derivatives as CDK12/13 Inhibitors | CDK1, CDK12, CDK11A | DYRK1A 509/4885GAA 4790/4885NPC1 3807/4885 |
| US-20240199611-A1 | ANTIBACTERIAL COMPOUNDS | FDPS, MT-ND4, NDUFS3 | DYRK1A 4544/4885GAA 424/4885NPC1 974/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | DYRK1A 3907/4885GAA 915/4885NPC1 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.